PDGFRα/β expression correlates with the metastatic behavior of human colorectal cancer: A possible rationale for a molecular targeting strategy

As new multi-target tyrosine kinase inhibitors are emerging in the therapy of various malignancies, our aim was to define the co-expression pattern of receptor-tyrosine-kinase platelet-derived growth factor receptors alpha and beta (PDGFRalpha/beta) in human colorectal cancer. The co-expression pattern of PDGFRalpha/beta was analyzed by RT-PCR in 99 histologically confirmed human colorectal carcinomas and five colorectal cancer cell lines. In addition, immunohistochemical (IHC) staining was applied for confirmation of expression and analysis of receptor tyrosine kinase (RTK) localisation. The colorectal cancer cell lines that were analysed revealed varying expression intensities of PDGFRalpha and PDGFRbeta. The majority of human colorectal cancer specimens revealed a PDGFRalpha (83%) or PDGFRbeta (60%) expression. While PDGFRalpha showed a predominantly cytoplasmic staining in tumor cells as well as in stromal pericytes, PDGFRbeta was restricted to stromal pericytes only. Furthermore, PDGFRalpha expression significantly correlated with lymph node metastasis (P=0.0082) and advanced UICC stages III/IV (P=0.018) in older patients (P=0.043). PDGFRbeta expression only revealed a trend towards lymphatic dissemination (P=0.099). Co-expression of PDGFRalpha/beta occurred in 57% of the colorectal cancer samples, whereas another 29% of the samples depicted mono-expression of PDGFRalpha or PDGFRbeta. Notably, PDGFRalpha/beta expression significantly correlated with lymphatic metastasis (P=0.007) and advanced UICC stages III/IV (P=0.017) in older patients (P=0.03). In summary, our results revealed that PDGFRalpha/beta expression significantly correlates with lymphatic dissemination and therefore encourages application of PDGFRalpha/beta RTK-inhibitors within a combination therapy.

[1]  H. Huber,et al.  PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression. , 2007, Oncogene.

[2]  C. Cordon-Cardo,et al.  Autocrine PDGFR signaling promotes mammary cancer metastasis. , 2006, The Journal of clinical investigation.

[3]  W. Stadler.  Targeted agents for the treatment of advanced renal cell carcinoma , 2005, Cancer.

[4]  D. Guidolin,et al.  A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma , 2004, Thrombosis and Haemostasis.

[5]  S. Baruchel,et al.  Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling. , 2006, Cancer research.

[6]  Kazuhiro Yoshida,et al.  Expression of several growth factors and their receptor genes in human colon carcinomas , 1990, Virchows Archiv. B, Cell pathology including molecular pathology.

[7]  T. Skorski,et al.  Oncogenic tyrosine kinases and the dna-damage response , 2002, Nature Reviews Cancer.

[8]  J. Coxhead,et al.  Mutations in APC, Kirsten-ras, and p53—alternative genetic pathways to colorectal cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[10]  K. Hristova,et al.  Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. , 2006, Biochemistry.

[11]  C. Bucana,et al.  Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  H. Koprowski,et al.  Expression of A-type PDGF receptor in cytoplasm of tumor cell lines synthesizing PDGF. , 1989, Experimental and molecular pathology.

[13]  A. Jemal,et al.  Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. , 2003, Journal of the National Cancer Institute.

[14]  L. Chow,et al.  Sunitinib: from rational design to clinical efficacy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  I. Fidler,et al.  Simultaneous Blockade of Platelet-Derived Growth Factor-Receptor and Epidermal Growth Factor-Receptor Signaling and Systemic Administration of Paclitaxel as Therapy for Human Prostate Cancer Metastasis in Bone of Nude Mice , 2004, Cancer Research.

[16]  X. Rogiers,et al.  Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases. , 2007, Cancer letters.

[17]  Toshio Ohhashi,et al.  PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. , 2004, Cancer cell.

[18]  D. August,et al.  Clinical perspective of human colorectal cancer metastasis , 2004, Cancer and Metastasis Reviews.

[19]  C. Bucana,et al.  Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. , 2006, The American journal of pathology.

[20]  Christopher J Drake,et al.  Genes critical to vasculogenesis as defined by systematic analysis of vascular defects in knockout mice. , 2005, The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology.

[21]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Kathleen R. Cho,et al.  Suppressor gene alterations in the colorectal adenoma‐carcinoma sequence , 1992, Journal of cellular biochemistry. Supplement.

[23]  C. Bucana,et al.  Expression of activated platelet‐derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential , 2006, International journal of cancer.

[24]  C. Mol,et al.  Switching on kinases: oncogenic activation of BRAF and the PDGFR family , 2004, Nature Reviews Cancer.

[25]  C. Yiannoutsos,et al.  Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. , 2006, Oncogene.

[26]  F. Huang,et al.  Platelet‐derived growth factor‐B increases colon cancer cell growth in vivo by a paracrine effect , 1995, Journal of cellular physiology.

[27]  N. Morton,et al.  Dominant genes for colorectal cancer are not rare , 1992, Annals of human genetics.

[28]  K. Kinzler,et al.  The multistep nature of cancer. , 1993, Trends in genetics : TIG.

[29]  E. Liu,et al.  Receptor tyrosine kinases expressed in metastatic colon cancer , 1995, International journal of cancer.

[30]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[31]  P. Kyzas,et al.  Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2 , 2005, Modern Pathology.

[32]  Kazuhiro Yoshida,et al.  Coexpression of Platelet‐derived Growth Factor (PDGF) A‐Chain and PDGF Receptor Genes in Human Gastric Carcinomas , 1989, Japanese journal of cancer research : Gann.

[33]  M. F. Booth,et al.  What brings pericytes to tumor vessels? , 2003, The Journal of clinical investigation.

[34]  L. Seymour,et al.  Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer , 2004, Breast Cancer Research and Treatment.

[35]  H. Stenmark,et al.  Defective downregulation of receptor tyrosine kinases in cancer , 2004, The EMBO journal.